Latest News

ctDNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA drops predict longer PFS.

FDA grants priority review to T-DXd for high-risk HER2-positive early breast cancer with residual disease, after trial shows markedly better recurrence-free survival than T-DM1.

New data push ADCs earlier, reshaping HER2+ metastatic breast cancer sequencing, maintenance, and trial strategy.

The FDA approves a new formulation of piflufolastat F 18, enhancing prostate cancer imaging with improved efficiency and patient access.

FDA’s February oncology surge brings new pancreatic TTFields, PD-1 win in ovarian cancer, AI tools, and key trial setbacks.

The combination of durvalumab and tremelimumab improved disease-free survival compared with active monitoring but efficacy came with increased toxicity.

Johns Hopkins Medicine develops a free immune atlas of pancreatic cancer trials, spotlighting blood-based signals to build stronger pancreatic cancer immunotherapy combinations.

During a live event, Joshua Richter, MD, explored proactive adverse event management when using selinexor in multiple myeloma.

Hi-C on routine FFPE biopsies uncovers hidden lymphoma drivers, enhancer hijacking, and PD-L1 rearrangements, guiding targeted therapy beyond FISH.

Dr Ghatalia discusses RETAIN-2, highlighting ctDNA analysis drawn from RETAIN-1 and RETAIN-2.

The FDA granted approval of the combination of teclistamab and daratumumab for patients with 1-3 prior lines of therapy in myeloma.

Sagar Lonial, MD, discusses the significance of the MRD end point for the ongoing priority review of iberdomide in multiple myeloma.

The FDA has granted a priority review and accepted the NDA for rusfertide in PV.

In an interview, Vincent Ma, MD, discussed how ctDNA levels after the first cycle of immune checkpoint inhibitor in melanoma could shed light on clinical outcomes.

During a live event, Hagen Kennecke, MD, discussed key trials shaping the treatment landscape of PNETs.

Modeling shows zanubrutinib may cut progression and costs versus acalabrutinib in relapsed/refractory CLL, especially in high-risk patients.

Adding nivolumab/ipilimumab to liver-directed melphalan improved outcomes in patients with metastatic uveal melanoma.

Efficacy and safety results from the phase 1 PAnTHA study presented at 2026 ASCO GU.

Induction ipilimumab/nivolumab plus chemoradiotherapy consolidation was associated with bladder preservation in muscle-invasive urothelial carcinoma.

Logic-gated CAR T A2B543 enters EVEREST-2 arm 2, adding membrane-tethered IL-12 to boost solid-tumor potency while limiting toxicity.

FDA clears real-time AI OCT to spot breast cancer margins during lumpectomy, helping surgeons reduce repeat operations and improve outcomes.

Clinical validation results show changes in methylated circulating tumor DNA (ctDNA) measured prior to treatment initiation and before cycle 3 of therapy were strongly associated with objective response and clinical benefit.

AKY-1189 gains fast track designation in urothelial cancer.

CAPItello-281 shows capivasertib plus abiraterone extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

IMvigor011 shows post-cystectomy ctDNA timing and levels predict relapse, while adjuvant atezolizumab clears ctDNA and extends survival in MIBC.

FDA grants tentative approval to PNT2003, a Lutathera radioequivalent PRRT for SSTR+ GEP-NETs, paving way for wider access by 2026.

Erica Pimenta, MD, PhD, discussed the goals and key findings from her and her colleagues’ research into IGF-1 and GLP-1 signaling pathways in liposarcoma.

New study links Medicaid expansion to sustained breast cancer survival gains, revealing uneven benefits by race and urging policy action.

Experts explain how MRI trends, seizures, and spectroscopy guide when IDH-mutant glioma monitoring ends and radiation or chemo begins.

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.